<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371396</url>
  </required_header>
  <id_info>
    <org_study_id>5RL-1DK081187</org_study_id>
    <nct_id>NCT01371396</nct_id>
  </id_info>
  <brief_title>Effect of Dietary Macronutrient Composition</brief_title>
  <official_title>Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand why Hispanics who are overweight have a higher
      incidence of fatty liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is a major factor driving the increased prevalence of hepatic steatosis in the US.
      However, little is known regarding the relationship between dietary intake and hepatic fat
      deposition or about the factors that promote loss of hepatic steatosis. Here, the
      investigators will determine how differences in dietary composition affect the development
      and regression of fatty liver. The investigators hypothesize that Hispanic subjects with
      metabolic syndrome will have higher liver fat synthesis rates compared to African American
      subjects.

      Using detailed in vivo, serial measurements of fuel metabolism (GC/MS and NMR) fatty acid
      metabolism will be measured in the liver and periphery. This will be the first study in which
      these two methodologies are used together to assess both glucose and fatty acid metabolism in
      the same subjects. Subjects will be tested before and after a dietary weight-loss
      intervention producing 6% body weight loss over 5 months.

      The specific aims are as follows:

      AIM 1: Determine the contribution of peripheral and dietary fat to liver-TG in Hispanics and
      African Americans with metabolic syndrome.

      Hypothesis: De novo lipogenesis will contribute to liver-TG in greater quantities compared to
      African Americans.

      AIM 2: Determine the effects of low-CHO and low-fat diets on liver fat regression.

      Hypothesis: Compared to a low-fat diet, a low-CHO diet will markedly decrease markers of
      inflammation coincident with greater improvements in insulin sensitivity as assessed by an
      intravenous glucose tolerance test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2007</start_date>
  <completion_date type="Actual">December 31, 2013</completion_date>
  <primary_completion_date type="Actual">December 31, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>de novo lipogenesis</measure>
    <time_frame>Change from Baseline in fatty acid synthesis at 5 months</time_frame>
    <description>In vivo measurement is made of liver fatty acid synthesis using stable isotope administration and analysis of plasma samples by GS/MS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary fatty acid clearance to liver</measure>
    <time_frame>Change from Baseline in dietary fat clearance at 5 months</time_frame>
    <description>Using a dietary stable isotope we will quantitate fat absorption and recycling of fat through the liver.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose fatty acid flux</measure>
    <time_frame>Change from Baseline in adipose fat flux at 5 months</time_frame>
    <description>A stable isotope is infused and the rate of adipose fatty acid release is calculated after analyzing blood samples.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Hispanic subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will identify as Hispanic ethnicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>African American subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will self-identify as African American in origin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-fat diet</intervention_name>
    <description>The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.</description>
    <arm_group_label>African American subjects</arm_group_label>
    <arm_group_label>Hispanic subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-carbohydrate diet</intervention_name>
    <description>The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.</description>
    <arm_group_label>African American subjects</arm_group_label>
    <arm_group_label>Hispanic subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elevated serum ALT or metabolic syndrome

          -  African American or Hispanic

          -  Nondiabetic

          -  Men or women

          -  Smokers and nonsmokers

          -  Pre- and post-menopausal (+/- HRT)

          -  Stable body weight

          -  Age 20-65 years

          -  BMI between 25-45 kg/m2

        Exclusion Criteria:

          -  Diabetes or Pregnancy

          -  Ethanol intake: males &gt; 140 g/week, females &gt; 70 g/week

          -  Chronic hepatitis B or chronic hepatitis C

          -  Hemochromatosis or Wilson's Disease

          -  Autoimmune hepatitis or primary biliary cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth J Parks, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTSW Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Nutrition</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shetty S, Ramos-Roman MA, Cho YR, Brown J, Plutzky J, Muise ES, Horton JD, Scherer PE, Parks EJ. Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology. 2012 Jan;153(1):113-22. doi: 10.1210/en.2011-1339. Epub 2011 Nov 1.</citation>
    <PMID>22045665</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramos-Roman MA, Sweetman L, Valdez MJ, Parks EJ. Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity. Metabolism. 2012 Feb;61(2):202-12. doi: 10.1016/j.metabol.2011.06.008. Epub 2011 Aug 5.</citation>
    <PMID>21820684</PMID>
  </results_reference>
  <results_reference>
    <citation>Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011 Dec 7;14(6):804-10. doi: 10.1016/j.cmet.2011.11.004.</citation>
    <PMID>22152305</PMID>
  </results_reference>
  <results_reference>
    <citation>Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, He T, Nair LA, Livingston KA, Fu X, Merritt ME, Sherry AD, Malloy CR, Shelton JM, Lambert J, Parks EJ, Corbin I, Magnuson MA, Browning JD, Burgess SC. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest. 2016 Apr 1;126(4):1605. doi: 10.1172/JCI86695. Epub 2016 Apr 1.</citation>
    <PMID>27035816</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JJ, Lambert JE, Hovhannisyan Y, Ramos-Roman MA, Trombold JR, Wagner DA, Parks EJ. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr. 2015 Jan;101(1):34-43. doi: 10.3945/ajcn.114.092262. Epub 2014 Nov 19.</citation>
    <PMID>25527748</PMID>
  </results_reference>
  <results_reference>
    <citation>Lambert JE, Parks EJ. Getting the label in: practical research strategies for tracing dietary fat. Int J Obes Suppl. 2012 Dec;2(Suppl 2):S43-50. doi: 10.1038/ijosup.2012.22. Epub 2012 Dec 11. Review.</citation>
    <PMID>27152153</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Elizabeth Parks</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Non-alcoholic fatty liver disease</keyword>
  <keyword>Obesity Metabolism</keyword>
  <keyword>Stable isotopes</keyword>
  <keyword>Dietary weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

